Scarica l'app Stockscreener
34.97
0.85%
-0.30
Dopo l'orario di chiusura:
34.93
-0.04
-0.11%
Precedente Chiudi:
$35.27
Aprire:
$35.43
Volume 24 ore:
1.06M
Relative Volume:
1.09
Capitalizzazione di mercato:
$1.88B
Reddito:
-
Utile/perdita netta:
$-119.95M
Rapporto P/E:
-17.38
EPS:
-2.0123
Flusso di cassa netto:
$-95.28M
1 W Prestazione:
-5.82%
1M Prestazione:
-3.45%
6M Prestazione:
+128.56%
1 anno Prestazione:
+303.81%
Intervallo 1D:
$34.87
$36.67
Intervallo di 1 settimana:
$34.87
$38.29
Portata 52W:
$7.80
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
34.97 | 1.90B | 0 | -119.95M | -95.28M | -2.0123 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-06 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-21 | Ripresa | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
TYRA Initiates Coverage On by Guggenheim -- Price Target Announced at $54.00 - GuruFocus
This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $54 - 富途牛牛
Guggenheim Initiates Tyra Bioscience at Buy With $54 Price Target - marketscreener.com
Guggenheim Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
TYRA (Nasdaq) Form 144: Director reports two 8,000-share transactions - Stock Titan
The Technical Signals Behind (TYRA) That Institutions Follow - Stock Traders Daily
Growth Stocks To Watch Today – April 10th - Defense World
JPMorgan Chase & Co. Trims Position in Tyra Biosciences, Inc. $TYRA - MarketBeat
IPO Launch: Is Tyra Biosciences Incs ROE strong enoughEntry Point & Precise Swing Trade Alerts - baoquankhu1.vn
FMR LLC holds 14.4% of Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Tyra Biosciences (NASDAQ:TYRA) Now Covered by Canaccord Genuity Group - Defense World
Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA) - MarketBeat
Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target - marketscreener.com
CCORF Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛
Canaccord Genuity initiates coverage of Tyra Biosciences (TYRA) with buy recommendation - MSN
Growth Stocks To Watch Now – April 3rd - Defense World
A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress - Yahoo Finance
Promising Growth Stocks To Watch Today – April 2nd - Defense World
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com
Tyra Bioscience Strengthens Financial Leadership with New Officer - TipRanks
Tyra Biosciences (TYRA) VP details multi-year stock option grants - Stock Titan
Tyra Biosciences names Julia Rueb principal accounting officer, succeeding Alan Fuhrman - TradingView — Track All Markets
Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer - Stock Titan
Tyra Biosciences, Inc. Announces Principal Accounting Officer Changes, Effective April 1, 2026 - marketscreener.com
Tyra Biosciences stock hits all-time high at 39.21 USD By Investing.com - Investing.com South Africa
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Growth Stocks Worth Watching – March 31st - Defense World
Precision Trading with Tyra Biosciences Inc. (TYRA) Risk Zones - Stock Traders Daily
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year HighWhat's Next? - MarketBeat
Tyra Biosciences stock hits all-time high at 39.21 USD - Investing.com
Tyra Biosciences (NASDAQ:TYRA) Trading 9.8% HigherShould You Buy? - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation - MSN
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock - MarketBeat
Tyra Biosciences director Kaplan sells shares worth $528k By Investing.com - Investing.com India
Tyra Biosciences director Kaplan sells shares worth $528k - Investing.com
Tyra Biosciences (NASDAQ: TYRA) director exercises 67,467 options, sells and returns shares - Stock Titan
Insider plans sale of 53,172 TYRA shares via option exercise (TYRA) - Stock Titan
Piper Sandler reiterates Tyra Biosciences stock rating on oral therapy potential - Investing.com Canada
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Highs Report: Is Tyra Biosciences Inc forming a breakout patternChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Non Muscle Invasive Bladder Cancer Pipeline Expands As 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds Delveinsight CG Oncology, Janssen, Tyra Biosciences, Urogen Pharma - Mena FN
Dabo gratinib designation honors key Tyra Biosciences executives - tradersunion.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.5%Should You Sell? - MarketBeat
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance - Sahm
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):